Association of serum apoA-I with in-stent restenosis in coronary heart disease

[1] Taniwaki M(2014)4-year clinical outcomes and predictors of repeat revascularization in patients treated with new-generation drug-eluting stents: a report from the RESOLUTE All-Comers trial (A randomized comparison of a zotarolimus-eluting stent with an everolimus-eluting stent for percutaneous coronary intervention) J Am Coll Cardiol 63 1617-1625

[2] Stefanini GG(1999)Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome Circulation 100 1872-1878

[3] Silber S(2015)Prognostic role of restenosis in 10 004 patients undergoing routine control angiography after coronary stenting Eur Heart J 36 94-99

[4] Richardt G(2011)In-stent restenosis Cardiovasc Ther 29 190-198

[5] Vranckx P(2017)Difference of tissue characteristics between early and late restenosis after second-generation drug-eluting stents implantation—an optical coherence tomography study Circ J 81 450-457

[6] Serruys PW(2018)Optical coherence tomographic analysis of drug-eluting in-stent restenosis at different times: a STROBE compliant study Medicine (Baltimore) 97 e12117-1357

[7] Mehran R(2015)Mechanisms and patterns of intravascular ultrasound in-stent restenosis among bare metal stents and first- and second-generation drug-eluting stents Am J Cardiol 116 1351-462

[8] Dangas G(2014)Safety and efficacy of different paclitaxel-eluting balloons in a porcine model Rev Esp Cardiol (Engl Ed) 67 456-64

[9] Abizaid AS(2014)Drug-eluting stents and bare metal stents in patients with NSTE-ACS: 2-year outcome from the randomised BASKET-PROVE trial EuroIntervention 10 58-159

[10] Mintz GS(2014)Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography Heart 100 153-802

[1] Taniwaki M(2014)4-year clinical outcomes and predictors of repeat revascularization in patients treated with new-generation drug-eluting stents: a report from the RESOLUTE All-Comers trial (A randomized comparison of a zotarolimus-eluting stent with an everolimus-eluting stent for percutaneous coronary intervention) J Am Coll Cardiol 63 1617-1625

[2] Stefanini GG(1999)Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome Circulation 100 1872-1878

[3] Silber S(2015)Prognostic role of restenosis in 10 004 patients undergoing routine control angiography after coronary stenting Eur Heart J 36 94-99

[4] Richardt G(2011)In-stent restenosis Cardiovasc Ther 29 190-198

[5] Vranckx P(2017)Difference of tissue characteristics between early and late restenosis after second-generation drug-eluting stents implantation—an optical coherence tomography study Circ J 81 450-457

[6] Serruys PW(2018)Optical coherence tomographic analysis of drug-eluting in-stent restenosis at different times: a STROBE compliant study Medicine (Baltimore) 97 e12117-1357

[7] Mehran R(2015)Mechanisms and patterns of intravascular ultrasound in-stent restenosis among bare metal stents and first- and second-generation drug-eluting stents Am J Cardiol 116 1351-462

[8] Dangas G(2014)Safety and efficacy of different paclitaxel-eluting balloons in a porcine model Rev Esp Cardiol (Engl Ed) 67 456-64

[9] Abizaid AS(2014)Drug-eluting stents and bare metal stents in patients with NSTE-ACS: 2-year outcome from the randomised BASKET-PROVE trial EuroIntervention 10 58-159

[10] Mintz GS(2014)Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography Heart 100 153-802